Stockreport

Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects [Seeking Alpha]

Beam Therapeutics Inc.  (BEAM) 
PDF The company has secured $675 million in upfront payments from agreements with Pfizer, Apellis, Verve, and Sana. Collaboration agreements boosted Beam's revenue in 202 [Read more]